Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.46 |
| ▸ | ECE1 | P42892 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP7 | P09237 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | GGT1 | P19440 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16673455 | 1.00 | ACE (0.46) | ACEECE1ITGB3ITGA2BMMP2 | |
| SCHEMBL16673181 | 0.91 | ACE (0.47) | ACE | |
| SCHEMBL16673188 | 0.91 | ACE (0.47) | ACE | |
| SCHEMBL16673178 | 0.87 | CA2 (0.43) | ITGB3ITGA2B | |
| SCHEMBL16673180 | 0.87 | CA2 (0.43) | ITGB3ITGA2B | |
| SCHEMBL4170377 | 0.85 | ACE (0.39) | ACEECE1 | |
| SCHEMBL4170380 | 0.85 | ACE (0.39) | ACEECE1 | |
| SCHEMBL9829792 | 0.84 | ITGB3 (0.49) | ACEITGB3ITGA2B | |
| SCHEMBL9829783 | 0.84 | ITGB3 (0.49) | ACEITGB3ITGA2B | |
| SCHEMBL9667576 | 0.84 | CTSC (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041157-B1 | PEPTIDE DERIVATIVES WITH THERAPEUTIC ACTIVITY | FLAMMA SPA (IT) | 2015-05-06 | — | — | EP | claimed |
| US-8765798-B2 | Peptide derivatives with therapeutic activity | FLAMMA S.P.A. (IT) | 2014-07-01 | — | — | US | claimed |
| US-20090247601-A1 | PEPTIDE DERIVATIVES WITH THERAPEUTIC ACTIVITY | FLAMMA S.P.A. (IT) | 2009-10-01 | — | — | US | claimed |
| EP-2041157-A1 | PEPTIDE DERIVATIVES WITH THERAPEUTIC ACTIVITY | Flamma S.P.A. (IT) | 2009-04-01 | — | — | EP | claimed |
| WO-2008001174-A1 | PEPTIDE DERIVATIVES WITH THERAPEUTIC ACTIVITY | FLAMMA, S.P.A. (IT) | 2008-01-03 | — | — | WO | claimed |
| EP-2041157-B1 | PEPTIDE DERIVATIVES WITH THERAPEUTIC ACTIVITY | FLAMMA SPA (IT) | 2015-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247601-A1 | PEPTIDE DERIVATIVES WITH THERAPEUTIC ACTIVITY | IAPP, VIP, DNPEP | ACE 277/4885ECE1 397/4885ITGB3 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.